For a radiologist, the difference between a 2D ultrasound slice and a full 3D volumetric image can be the difference between a guess and a diagnosis. PIUR Imaging, an Austrian medtech founded in 2015, is making a pragmatic bet that the path to better imaging runs through the machines already sitting in hospitals. Its software, cleared by the FDA and integrated with GE HealthCare LOGIQ systems, aims to upgrade existing scanners with AI-powered tomographic 3D capabilities [PIUR IMAGING, retrieved 2024].
A Wedge Into the Installed Base
The company's core proposition is a vendor-agnostic software layer. Its flagship product, PIUR tUS Infinity, is a standalone application that works with third-party ultrasound devices, while PIUR tUS inside is embedded directly into select GE HealthCare LOGIQ systems [PIUR IMAGING, retrieved 2024]. The approach sidesteps the price tag of a new 3D-capable scanner. The technology uses proprietary sensor technology and AI to reconstruct 3D volumes from standard 2D sweeps, promising standardized, reproducible examinations that can cut workflow time for procedures like thyroid scans by up to 60 percent [PIUR IMAGING, retrieved 2024].
The Regulatory and Partnership Footprint
Clinical adoption in medical imaging is a story of regulatory stamps and strategic alliances. The FDA's 510(k) clearance for PIUR tUS inside, announced in 2024, was a critical milestone [Diagnostic Imaging, retrieved 2026]. Having its software embedded within a major OEM's workflow is a significant distribution advantage. The company has also inked a partnership with radiopharmaceutical firm Curium to advance thyroid diagnostics in Germany [Curium Pharma, 2023-10-25].
Funding and the Path to Scale
To fuel its U.S. and European expansion, PIUR closed a €5.6 million (approximately $5.99 million) growth capital round in mid-2025, led by Aescuvest Capital Partners [Healthcare IT Today, 2025-07-30]. This followed a €4.9 million Series A in 2023 led by Ascend Capital Partners [The SaaS News, July 2023].
| Product | Description | Key Differentiator |
|---|---|---|
| PIUR tUS Infinity | Standalone AI software for tomographic 3D imaging | Vendor-agnostic; upgrades any third-party ultrasound system [PIUR IMAGING, retrieved 2024] |
| PIUR tUS inside | Integrated software solution | FDA-cleared and embedded within select GE HealthCare LOGIQ systems [PIUR IMAGING, retrieved 2024] |
| PIUR tUS Infinity 4 for Thyroid | Application-specific module | Combines 3D imaging with AI-based automation to standardize thyroid exams [PIUR IMAGING, retrieved 2024] |
The Competitive Landscape and Execution Risks
The field of ultrasound enhancement is crowded, but PIUR's retrofit angle sets it apart. Its competition falls into distinct camps:
- The Imaging Titans. Companies like GE HealthCare, Siemens Healthineers, and Philips sell integrated 3D/4D ultrasound as a premium feature. PIUR's software potentially complements them by adding functionality to older models.
- The Handheld Disruptors. Startups like Butterfly Network and Clarius Mobile Health are democratizing access with lower-cost, portable hardware. PIUR's bet is the opposite: it assumes hospitals will keep their existing, often superior, cart-based systems.
- The Software Specialists. Competitors like TomTec Imaging Systems also provide advanced ultrasound analysis software. PIUR's differentiation rests on its specific focus on tomographic 3D reconstruction and its embedded partnership with a major OEM.
The primary risk for PIUR is one of commercial execution in a slow-moving, relationship-driven market. Scaling beyond the initial OEM relationship will be the next test.
The Patient at the Center
PIUR's initial focus areas, thyroid and carotid imaging, address conditions where precise volumetric measurement directly impacts management. In thyroid cancer, accurate 3D sizing of nodules is critical for determining whether to monitor or biopsy. PIUR's proposition is to replace manual estimation with an automated, AI-assisted 3D volumetric calculation, aiming for a more consistent, quantitative baseline for tracking disease progression over time. The capital from its 2025 round is earmarked for scaling in the U.S. and Europe [PIUR IMAGING, retrieved 2024].